f Adeno-associated virus type 2 (AAV2) has gained much interest as a gene delivery vector. A hallmark of AAV2-mediated gene transfer is an intracellular conformational change of the virus capsid, leading to the exposure of infection-relevant protein domains. These protein domains, which are located on the N-terminal portion of the structural proteins VP1 and VP2, include a catalytic phospholipase A 2 domain and three clusters of basic amino acids. We have identified additional protein sequence motifs located on the VP1/2 N terminus that also proved to be obligatory for virus infectivity. These motifs include signals that are known to be involved in protein interaction, endosomal sorting and signal transduction in eukaryotic cells. Among different AAV serotypes they are highly conserved and mutation of critical amino acids of the respective motifs led to a severe infectiondeficient phenotype. In particular, mutation of a YXXQ-sequence motif significantly reduced accumulation of virus capsids around the nucleus in comparison to wild-type AAV2. Interestingly, intracellular trafficking of AAV2 was shown to be independent of PLA 2 activity. Moreover, mutation of three PDZ-binding motifs, which are located consecutively at the very tip of the VP1 N terminus, revealed a nuclear transport-defective phenotype, suggesting a role in nuclear uptake of the virus through an as-yet-unknown mechanism.
F
or more than 10 years, vectors based on the adeno-associated virus (AAV) have been exploited extensively as gene transfer tools for therapeutic applications. Several positive features, including their nonpathogenicity, replication deficiency, long-term gene expression, low integration rate into human chromosomes, and broad tissue tropism, make AAV vectors suitable for clinical gene therapy. A multitude of clinical studies have been investigating the usability, safety, and efficiency of AAV vectors for the treatment of monogenic disorders such as hemophilia, cystic fibrosis, Leber's congenital amaurosis, and a number of more complex diseases, including Parkinson's and cancer (10, 36, 38, 55) . However, the efficiency of AAV-mediated gene transfer is limited at the cellular level by three major barriers: (i) by cell binding and entry, (ii) by postentry trafficking, and (iii) nuclear entry. Thus, detailed analysis of the AAV infection process is essential for the development of improved gene therapy vectors.
AAV belongs to the family of Parvoviridae, which are small, nonenveloped viruses with a single-stranded DNA genome. Their icosahedral capsid is formed by three viral proteins-VP1, VP2, and VP3-which share overlapping open reading frames, all having the sequence of VP3 in common. VP1 and VP2 differ from VP3 by N-terminal extensions of 138 and 65 additional amino acids, respectively. The infection cycle of AAV2 is initiated by binding to cellular receptors, including heparan sulfate proteoglycan, ␣ v ␤ 5 integrin, ␣ 5 ␤ 1 integrin, fibroblast growth factor receptor 1, hepatocyte growth factor receptor 1, and 36/67-kDa laminin receptor (1, 4, 31, 46, 53, 54) and subsequent endocytosis into the cell. Earlier studies have suggested that AAV2 enters the cell via clathrin-coated pits (5, 14) , while more recent work has identified a main entry pathway via clathrin-independent endosomal compartments (42) . After internalization, AAV2 is transported within endosomal vesicles close to the nucleus. Intracellular transport of AAV2 involves the passage through different endosomal compartments, and routing was suggested to be dependent on the cell type and virus dose used in the respective study (12, 22, 44) . Different research groups described transport through the cytoplasm either via early endosomes (5, 49, 60) , early and late endosomes (13) , or early and both late and perinuclear recycling endosomes (12) or via endosomal compartments and the trans-Golgi network (42, 44) . During or following vesicular transport to the nuclear area, virus particles are released into the cytoplasm before they enter the nucleus for replication, gene expression and de novo capsid assembly (39, 50) . According to a majority of studies, AAV2 enters the nucleus fully assembled (5, 30, 50, 60) ; however, Lux et al. (37) proposed that AAV2 genomes enter the nucleus, while virus capsids remain at the cytoplasmic face. Whether AAV2 is traversing the nuclear membrane via the nuclear pore complex (NPC) or by means of an alternative entry mechanism has not been elucidated thus far. With a diameter of 26 nm, AAV2 capsids are small enough for being transported through NPCs and, in fact, one nuclear localization signal (NLS)-like sequence motif, termed basic region 3 (BR3), has been shown to be infection relevant and has thus been suggested to be responsible for AAV2 nuclear import (19) . However, two studies found evidence for a nonclassical NPC-independent import pathway. Inhibition of NPC-mediated nuclear import by thapsigargin, wheat germ agglutinin (WGA), or an antibody (Ab) directed against p62 did not block nuclear accu-mulation of AAV2 DNA or uptake of fluorescently labeled AAV2 into nuclei in vitro (23, 60) .
During their passage through endosomal compartments, AAV2 capsids encounter a critical conformational change, leading to the exposure of the N-terminal portion of capsid proteins VP1 and VP2, which until the change in conformation are hidden within the capsid, to the outer capsid surface (6, 34, 50) . Exposure of VP1/2 N termini is most probably triggered by the acidic environment of endosomes and possibly also by the endosomal proteases cathepsins D and L, since inhibition of endosomal acidification or blocking of cathepsin D/L activity negatively interferes with AAV2 infection (2, 5, 50) . Masking of VP1/2 N termini by specific antibodies negatively interferes with AAV2 infection, when they are applied in the cytoplasm or the nucleus, suggesting that these sequences are accessible in those cellular compartments. VP1/2 N termini of AAV2 harbor a conserved catalytic phospholipase A 2 (PLA 2 ) domain and three basic regions, which resemble classical NLS (17, 27, 62) . The PLA 2 domain has been described as necessary for endosomal escape (16, 51) and the basic regions contribute to virus infectivity, possibly by enabling the nuclear import of capsids (19, 27, 50, 59) . Mutation of basic regions 2 and 3 not only diminishes AAV2 infectivity but also seems to affect both cytoplasmic and intranuclear transport between nucleoli and nucleoplasm (29) .
Exposure of VP1/2 N termini to the capsid surface aids virus infectivity by presenting viral domains, thereby enabling infection-promoting virus-cell interactions. Assuming that a multitude of virus-cell interactions are necessary for a productive infection, we hypothesized that the VP1/2 N termini contain additional functional sequences, besides the ones described thus far. Indeed, a sequence analysis program predicted a number of protein sequence motifs, including one YXX⌽ and one leucine-based sorting signal as well as three consecutive PDZ-and three SH2-binding motifs. Mutation of the respective motifs dramatically decreased virus infectivity, while capsid assembly and genome packaging remained unaffected. Exposure of VP1/2 N termini was not blocked in the mutant capsids. However, the intracellular transport pattern resulting in nuclear accumulation, as well as the nuclear entry of capsids, was affected by the change of specific sequence motifs.
MATERIALS AND METHODS
Plasmids and site-directed mutagenesis. Plasmid pTAV2.0 (26) contains the entire AAV2 genome from pAV-2 (35), including both inverted terminal repeats (ITRs), cloned into the BamHI site of plasmid pBluescript II. The constructs Y6A, D9A/D13A/E17A, P27D, P29E, L45E/V46A, Y50A, Y52A, E63A, Y79A/Q82A, Q82A, Y90A, L131A/V132A, T159A, and T176A are based on pTAV2.0, containing the designated mutations in the cap gene of AAV2. The plasmid pJ407 (32) -containing the BamHINotI fragment of pTAV2.0 in a pUC131 backbone-was used as a template for site-directed mutagenesis of the AAV2 cap gene. Mutagenesis was performed using a QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's manual. The SwaI-BsiWI fragment of mutated pJ407, containing the desired mutation, was subsequently subcloned into pTAV2.0. Mutations have been verified by DNA sequencing. The constructs pHD/AN (17) (contains amino acid exchanges within the catalytic center of the PLA 2 domain), pTAV2.0-⌬VP1 (34) , and pXX6 (61) have been described previously.
Transfection of 293T cells and preparation of virus supernatants. 293T cells were seeded in 10-cm culture dishes at a density of 1.5 ϫ 10 6 cells per dish in 10 ml of culture medium (Dulbecco modified Eagle medium [DMEM] supplemented with 10% fetal calf serum, 100 U of penicillin/ml, 100 g of streptomycin/ml, and 2 mM L-glutamine).
After 24 h, cells were transfected with 10 g of the respective pTAV 2.0 constructs and 10 g of pXX6 using the calcium phosphate method (40) . At 64 h posttransfection, the cells were harvested, washed with phosphate-buffered saline (PBS; 137 NaCl, 2.7 mM KCl, 8.3 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ), and resuspended in 1 ml of PBS-MK (PBS with 1 mM MgCl 2 and 2.5 mM KCl) with protease inhibitors (Roche) per dish. The cells were lysed by three freeze-thaw cycles (Ϫ80°C/37°C), and cellular debris was sedimented by centrifugation at 10,000 ϫ g for 5 min at 4°C.
Production and purification of virus stocks. For large-scale virus productions, 293T cells were seeded in 15-cm culture dishes at a density of 6 ϫ 10 6 cells per dish in 25 ml of culture medium. The next day (24 h), the cells were transfected with 25 g of the respective pTAV2.0 construct and 30 g of pXX6 as described above. At 64 h posttransfection, the cells were harvested, washed once with PBS, and resuspended in a total of 10 ml of lysis buffer (150 mM NaCl, 50 mM Tris-HCl [pH 8.5], 2 mM MgCl 2 ) with protease inhibitors (Roche) per dish. The cells were lysed by nine freezethaw cycles (Ϫ80°C/37°C), and then nonpackaged viral DNA and plasmid DNA was digested with 50 U of benzonase (Sigma)/ml for 30 min at 37°C. Cellular debris was removed by centrifugation at 5,000 ϫ g and 4°C for 40 min. Viruses were purified via two consecutive iodixanol step gradients as described previously (50) . For analysis of nuclear uptake and endosomal escape, viruses were additionally purified via a continuous iodixanol gradient as described previously (41) . Virus preparations were stored in 40% iodixanol at Ϫ80°C in aliquots.
Titration of virus stocks and analysis of viral protein expression. Capsid titers were determined by an AAV2-specific enzyme-linked immunosorbent assay (ELISA) as described by Grimm et al. (20) (Progen). Genome titers were determined by quantitative real-time PCR (qRT-PCR) using TaqMan universal PCR master mix (Applied Biosystems) and AAV2 rep-specific primers and probe as described previously (56) . Infectious titers were determined by Southern blotting with a rep-specific radioactive-labeled probe as described previously (6) . The expression of viral capsid proteins VP1, VP2, and VP3 was analyzed from purified virus preparations by Western blotting with the monoclonal Ab (MAb) B1 (58) .
Analysis of temperature-induced VP1 N terminus exposure. For the Western dot blot assay, a total of 2 ϫ 10 10 iodixanol-purified viral capsids, diluted in a volume of 200 l of PBS-MK, were exposed to room temperature, 60°C, 65°C, or 75°C for 5 min, respectively, followed by incubation on ice for 5 min. Thereafter, samples were transferred to a nitrocellulose membrane (PROTRan; Schleicher & Schuell) using a vacuum blotter. Membranes were incubated in blocking solution (PBS with 10% skimmed milk powder) for 1 h. For the detection of capsid epitopes, membranes were incubated with MAb A20, A1, or B1 (58) (hybridoma supernatants diluted 1:10 in blocking solution) for 1 h. After washing steps with PBS (5 ϫ 10 min), the membranes were incubated with a peroxidase-conjugated goat anti-mouse Ab (Dianova) for 1 h. Afterward, the membranes were washed again for 5 ϫ 10 min with PBS before the proteins were visualized by using an enhanced chemiluminescence detection kit (Amersham/GE Healthcare).
Production of recombinant VP1/2 N termini and analysis of PLA 2 activity. Amino acids 1 to 202 of the AAV2 VP1/2 N termini (in the wild type [wt] or the respective mutants) were N-terminally fused to a His 6 tag by cloning into the plasmid pET-30b (Novagen) and were expressed in Escherichia coli Rosetta using the autoinduction methodology (52) . His 6 -tagged VP1/2 N termini were purified from bacterial cultures by chromatography on Ni-NTA agarose (Qiagen) according to the manufacturer's manual. After elution from the Ni-NTA agarose column, the proteins were transferred to a PLA 2 activity buffer (50 mM HEPES [pH 7.0], 10 mM CaCl 2 ) via gel filtration using Zeba desalt spin columns (Thermo). For measuring PLA 2 activity, 18.15 g of purified VP1/2 N termini were used in a colorimetric sPLA 2 assay (Cayman Chemical) according to the manufacturer's instructions. The PLA 2 activity was measured once per h over a time period of 5 h.
Analysis of intracellular transport and nuclear uptake by confocal imaging. For the analysis of intracellular transport of virus particles, HeLa cells were seeded on coverslips, which have been placed in wells of a 24-well plate, at a density of 7 ϫ 10 4 cells/well in 500 l of culture medium. After 24 h, the medium was removed, and the cells were infected with 5 ϫ 10 5 double-iodixanol-purified viral capsids/cell (according to the capsid titer) in 200 l of DMEM with 50 mM HEPES (DMEM-i) for 1 h at 37°C; for a negative control, cells were incubated with DMEM-i only. After incubation, virus-containing medium was removed, and the cells were washed three times with DMEM-i. The cells were then further cultivated in 500 l of culture medium for the indicated time points. For analysis of nuclear uptake, 2 M MG132 was added to the medium throughout infection. The cells were fixed with 2% paraformaldehyde-PBS for 15 min at room temperature. To quench free aldehyde groups, cells were treated twice for 5 min each time with 50 mM NH 4 Cl-PBS before permeabilizing the membranes with 0.2% Triton X-100 -PBS for 10 min. The coverslips were washed three times for 5 min each time in PBS and then incubated for 1 h with MAb A20 (58) and goat anti-lamin B (Santa Cruz Biotechnology), diluted 1:100 in A20 hybridoma supernatant. For analysis of VP1/2 N terminus exposure, coverslips were incubated with MAb A69 hybridoma supernatant. After incubation with the primary antibodies, the cells were washed for 5 ϫ 10 min with PBS and then incubated for 1 h at 37°C with an Alexa 488-conjugated chicken anti-mouse Ab at 1:1,000 and an Alexa 594-conjugated chicken anti-goat Ab at 1:600 (Molecular Probes); secondary antibodies were diluted in PBS with 1% bovine serum albumin. Coverslips were washed five times for 10 min each time before they were mounted on glass slides using Permafluor mounting medium (Immunotech). Confocal images were taken with a Leica TCS SP2 or a Zeiss LSM 710 ConfoCor3 microscope, respectively, using a ϫ63 oil immersion objective lens and the filter settings for the corresponding Alexa dyes at a pinhole size of 1. Images were processed with Adobe Photoshop CS software and ImageJ. Processing was done simultaneously on the images to avoid selective shifts of brightness or contrasts. The distribution of virus particles was statistically analyzed from the unprocessed images using a MATLAB-based software.
Subcellular fractionation and analysis of endosomal fractions. HeLa cells were seeded in 15-cm culture dishes at a density of 3 ϫ 10 6 cells per dish in 25 ml of culture medium. After 24 h, cells were infected with 200 viral genomes (VGs)/cell of double-iodixanol-purified AAV2 wt or AAV2 mutants in 6 ml of DMEM-i. Viruses were attached to the cells for 1 h at 4°C before the cells were shifted to 37°C, followed by incubation for 1 h. The virus was then removed, and the cells were cultivated in 15 ml of culture medium for 15 h. Early endosomal fractions were prepared as described before (3, 18, 33) . Briefly, the cells were harvested and homogenized, and a postnuclear supernatant was prepared, adjusted to 40.6% sucrose-3 mM imidazole (pH 7.4), loaded onto the bottom of an SW60 tube, and overlaid sequentially with 35 and 25% sucrose solutions in 3 mM imidazole (pH 7. brane proteins, where they interact with adaptor proteins (AP) and thereby navigate molecular traffic, either from the plasma membrane or from the trans-Golgi network to endosomal and lysosomal compartments. PDZ domains are scaffolding modules that are involved in a variety of cellular functions, including the maintenance of cell-cell junctions, cellular polarity, and multiprotein signaling pathways (24) .
Comparison of the cap sequence (aa 1 to 202) of AAV2 to that of AAV serotypes 1 to 12 reveals that most of the protein sequence motifs identified in the AAV2 sequence are also found in other AAV serotypes (Fig. 1A) . The critical tyrosine residue of the YXX[LMVIF] sorting signal and the critical leucine of the [DER]XXXL[LVI] sorting signal, respectively, are completely conserved among AAV serotypes 1 to 12. One of the FHA-binding motifs at position 159 to 162 is not that well conserved; here, the critical threonine is solely present in AAV2 and was nonconservatively exchanged to isoleucine, valine, proline (nonpolar amino acids) or arginine (basic amino acids) in other AAV serotypes. However, the threonine of the FHA-binding motif at positions 176 to 179 is highly conserved, only being conservatively exchanged to serine in AAV5 and AAV12. All four PDZ-binding motifs are almost fully conserved, having only one aspartic acid to glutamic acid exchange in AAV5 (position 12) and isoleucine to leucine/valine exchanges in AAV4 and AAV5 (positions 15 and 19) . The critical tyrosine in all SH2-binding motifs is entirely conserved, except for one tyrosine-to-histidine-exchange in AAV5 at position 6. Looking at the SH3-binding motifs, completely conserved prolines are found in a PXP rather than in a PXXP pattern. Taken together, we see a high level of conservation regarding the described motifs.
Motifs on unique VP1 N termini play a critical role for AAV2
infectivity. This prompted us to produce and analyze capsid mutants of AAV2, carrying aa exchanges within respective protein sequence motifs (Fig. 1B) . They partially overlap with the PLA 2 domain but not with the basic regions. AAV2 mutants were analyzed for capsid assembly, genome packaging, infectivity and protein expression (Fig. 2) . Using the MAb A20-based capsid ELISA, we detected similar levels of fully assembled AAV2 wt and AAV2 variants (VP/ml; Fig. 2A ). Solely, mutant Y6A, with a 100-fold reduction in capsid titer, seems to be slightly deficient in capsid assembly. Furthermore, we quantified packaged AAV2 genomes (viral genomes [VG]) with qRT-PCR and related them to the capsid titer (VP/VG; Fig. 2B ). For AAV2 wt, the ratio of genomecontaining capsids to empty capsids is in the range of 1:100, while Fig. 2C ). For AAV2 wt, 1 in 2 genome-containing capsids was infectious, while in mutants D9A/ D13A/E17A, L45E/V46A, Y50A, Y52A, Y79A/Q82A, and Y90A only 1 in 1,000 to 1 in 100,000 genome-containing particles was infectious. These capsid mutants were thus defined to be infection deficient (indicated by tall bars in Fig. 2C ). Mutants, whose infectivity was either not reduced at all or reduced to Ͻ1,000-fold compared to AAV2 wt, were not assigned as infection deficient and hence were not further characterized. In this context, mutants Q82A and Y79A/Q82A are of particular interest. In both AAV2 variants the same SH2-binding motif, YXXQ, was mutated; in one case it was glutamine only (Q82A), and in the other case both tyrosine and glutamine (Y79A/Q82A) were mutated. However, whereas the Q82A mutant shows no significant decrease in infectivity, the Y79A/Q82A mutant is dramatically infection deficient. Thus, the tyrosine of this YXXQ motif seems to be required for AAV2 infectivity.
To further assure correctly assembled capsids, we analyzed VP1, VP2, and VP3 expression of AAV2 wt and infection-deficient mutants by Western blotting, showing approximately the same ratio of VP1:VP2:VP3 in all viruses analyzed (Fig. 2D) .
In summary, we conclude that exchanging critical amino acids of putative sorting signals or binding motifs on the VP1 N termini of AAV2 has no negative influence on capsid assembly and genome packaging but causes severe infection deficiency in some mutants. Mutating amino acids of PDZ-binding motifs (D9A/ D13A/E17A) and SH2-binding motifs (Y52A, Y79A/Q82A, Y90A), as well as sorting signals (L45E/V46A, Y50A), has a dramatic effect on infectivity, whereas alteration of FHA-binding motifs (T159A, T176A) and SH3-binding motifs (P27D, P29E) has no significant negative effect on AAV2 infection according to the criteria applied.
AAV2 mutants are able to externalize their VP1 N termini in vitro and during infection. After virus entry, AAV2 is taken up into endosomes where virus capsids undergo a conformational rearrangement leading to the exposure of VP1 N termini. To test whether the amino acid exchanges within the VP1 N termini affect the conformational change of the capsid, we induced VP1 N termini externalization by limited heat treatment as described previously (6, 34) . Specific MAbs were used to detect assembled capsids (A20), externalized VP1 N termini (A1), and disassembled capsid proteins (B1) (57) in a native Western dot blot (Fig. 3A) . The presence of intact capsids was confirmed for AAV2 wt and capsid mutants after heat treatment of up to 65°C (Fig. 3B, A20 signal) . Externalization of VP1 N termini was observed upon exposure of capsids to 60°C and, more prominently, to 65°C. In some cases, a slight A1 signal can be seen in untreated virus samples (room temperature [RT]) which, however, correlates with a B1 signal, indicating that virus samples contain a small amount of alreadydisassembled capsids.
For testing the ability of VP1 N terminus exposure during infection, we infected HeLa cells with AAV2 wt and two of the infectiondeficient mutants (D9A/D13A/E17A and Y79A/Q82A), respectively, and analyzed VP1/2 N terminus exposure by indirect immunofluorescence using MAb A69 (Fig. 3C) . We chose to analyze the indicated capsid mutants because they showed distinct phenotypes in intracel- lular trafficking and nuclear uptake (see Fig. 5 and 6 ). Fluorescence microscopy revealed that the VP1/2 N termini are not accessible for MAb A69 at 0 h postinfection but become exposed during the infection process (green signals at 4 h postinfection). From these results we conclude that the infection-deficient phenotypes observed for these capsid mutants cannot be assigned to hindered exposure of VP1 N termini to the capsid surface.
Analysis of PLA 2 activity of AAV2 VP1 N terminus mutants. VP1 N termini of AAV2 harbor a catalytic PLA 2 domain that has been described as a critical factor for successful virus infection (17, 62) . Most of the sorting signals and binding motifs, which lead to an infection-deficient phenotype upon mutation, are located within the PLA 2 domain (Fig. 1) . We thus analyzed their potential influence on the catalytic function of the PLA 2 domain by measuring the PLA 2 activity. As a positive control we used bee venom PLA 2 ; as negative controls we used a PLA 2 deletion mutant (VP1/2 N-⌬XhoI) and a previously described PLA 2 inactive mutant, carrying amino acid exchanges within the catalytic center (VP1/2 N-H75A/D76N) (17) . Figure 4A shows the kinetics of PLA 2 activity of VP1/2 N termini expressed in E. coli and purified by His tag affinity chromatography. In wt VP1/2 N termini (line with black squares) the PLA 2 activity was rising to a similar level as in the positive control (line). No activity was observed for the PLA 2 deletion mutant and VP1/2 N-H75A/D76N. There was also no catalytic activity detectable in VP1/2 N mutants, whose amino acids have been exchanged within the PLA 2 domain: VP1/2 N-L45E/ V46A, -Y50A, -Y52A, -Y79A/Q82A, and -Y90A. A lower but measurable PLA 2 activity was found in the triple mutant VP1/2 N-D9A/D13A/E17A (line with red circles). However, we used a constant amount of protein in this assay, corresponding to the protein concentration of purified, recombinant VP1/2 N termini, which was determined by spectrophotometry. Due to a high level of proteolytic degradation of the triple mutant (Fig. 4C) , the VP1/2 N-D9A/D13A/E17A sample contained less full-length (36-kDa) protein than the wt or any other VP1/2 N mutant. We thus conclude that the lower level of PLA 2 activity of the triple mutant compared to wt VP1/2 N termini is likely due to the lower amount of catalytically active protein used in the assay. Consistently, the addition of 2-or 4-fold more triple mutant to the assay resulted in a rising PLA 2 activity (Fig. 4B) . Quantification of full-length VP1/2 N termini of the wt and triple mutant, respectively, revealed that a sample of triple mutant containing 83.2% of full-length protein had a relative PLA 2 activity of 50% with respect to the wt PLA 2 activity (Fig. 4D) .
From these observations we can conclude that all mutants with the exception of the triple mutant D9A/D13A/E17A are PLA 2 defective. This PDZ-binding motif triple mutant has an overall PLA 2 activity of 60% compared to wt PLA 2 . Consequently, its 1,000-fold reduced infectivity cannot be explained by a complete lack of PLA 2 activity.
Some infection-deficient AAV2 VP1 N-terminal mutants show a trafficking phenotype. Since some domains of VP1 N termini were shown to be obviously infection relevant, we investigated the effect of mutated sorting signals and binding motifs on intracellular trafficking by immunofluorescence. HeLa cells were infected with either AAV2 wt or infection-deficient capsid mutants, and their intracellular location was visualized using MAb A20, detecting assembled capsids (Fig. 5A) . At 5 h postinfection we observed different localization patterns. Three phenotypes could be distinguished: (i) a wt-like accumulation and clustering of viral particles around the nucleus; (ii) a mixed phenotype, with some clustered virions plus some scattered virions; and (iii) a prominently scattered phenotype, with only few clustered virions in the nuclear periphery. ⌬VP1, which lacks the entire VP1 N terminus including the PLA 2 domain and most of the potential sorting signals and binding motifs, is most abundantly scattered throughout the cytoplasm. In contrast, PLA 2 -inactive mutant H75A/D76N predominantly forms wt-like clusters around the nucleus. SH2-binding motif mutant Y79A/Q82A showed a scattered phenotype, similar to that of ⌬VP1, although it is also PLA 2 inactive. All other infection-deficient mutants displayed mixed forms of these extreme phenotypes.
For a quantitative analysis, we analyzed data sets of 32 to 91 virus-infected cells using a MATLAB-based image analysis software to calculate the distances among all virus-containing focireferred to as "interparticle distance"-of each infected cell. Minor interparticle distances indicate virus clustering, while scattered virions are represented by major interparticle distances. (Fig. 5B) . Note that virus clustering was only observed in close proximity to the nucleus, whereas scattered virions were found throughout the cytoplasm. The box plots confirm our notion of differently distributed capsid mutants compared to AAV2 wt. While 75% of AAV2 wt particles cluster with interparticle distances of Ͻ77.5 pixels, ⌬VP1 and Y79A/Q82A exhibited a much broader particle distribution with interparticle distances of up to 292 pixels (maximum Y79A/Q82A). The distribution patterns of mutants H75A/D76N, L45E/V46A, and Y52A resembled a wt-like clustering phenotype, whereas D9A/D13A/E17A, Y50A, and Virus particles were stained with the MAb A20 and an Alexa 488-conjugated secondary Ab (green), and nuclei were visualized with anti-lamin B Ab and an Alexa 594-conjugated secondary Ab (red). Confocal images were taken with a Leica SP2 LSM using a ϫ63 oil immersion objective; the plane of focus was set to the vertical center of the cell. (B) Schematic depiction explaining how the intracellular virus particle distribution was analyzed quantitatively. Red ellipse, nucleus; green hexagon, virus particle; black line, distance. Using MATLAB-based image analysis software, interparticle distances (pixel) among all virus-containing foci of each infected cell were determined. (C) The degree of particle distribution of each AAV2 variant is depicted graphically in a box diagram. Data from top to bottom: maximum (upper cross), 75% quantile (top line), mean (black square), 50% quantile (middle line), 25% quantile (bottom line), and minimum (lower cross). Capsid mutants whose particle distribution differs significantly from that of AAV2 wt are labeled with an asterisk (*) (Wilcoxon rank sum test with continuity correction; P Ͻ 0.05).
Y90A displayed an intermediate phenotype. Statistical analysis (Wilcoxon rank sum test with continuity correction; significance level of 95%) proved a significant difference in the distribution patterns of ⌬VP1 (P ϭ 0.0338) and Y79A/Q82A (P ϭ 0.0087) compared to that of AAV2 wt. These findings suggest a PLA 2 -independent endosomal trafficking mechanism for AAV2, in which an SH2-binding motif (YXXQ) plays a role. Knocking out PLA 2 function only (H75A/D76N) is not sufficient for giving rise to an abnormal trafficking pattern.
AAV2 with defective PDZ-binding motifs does not enter the nucleus. After perinuclear accumulation and release of virus particles into the cytoplasm, AAV2 enters the nucleus as an intact virion with externalized VP1/2 N termini (50). The exact mechanism which is used by AAV to pass the nuclear membrane has not been described, yet. Since the infection-deficient but PLA 2 -active PDZ-binding motif triple mutant did neither shows a defect in VP1 N terminus exposure (Fig. 3) nor an abnormal intracellular trafficking pattern (Fig. 5) , we sought to investigate the nuclear uptake of this mutant. To this end, we infected HeLa cells with AAV2 wt, ⌬VP1, or the PDZ-binding motif triple mutant D9A/ D13A/E17A, respectively, in the presence of proteasome inhibitor MG132 and analyzed the nuclear uptake of intact virions by immunofluorescence microscopy. AAV2 infection in the presence of MG132 enables the visualization of intact virions that accumulate in the nucleus, as has been shown by Johnson et al. (29) . At 16 h postinfection, we see a clear accumulation of AAV2 wt intact capsids in the nuclei of infected cells, whereas mutants ⌬VP1 and D9A/D13A/E17A remain outside the nucleus (Fig. 6A) .
The localization pattern of the mutants could either result from a defect in endosomal release or from an inability to penetrate the nuclear envelope. To investigate these possibilities, we infected HeLa cells with AAV2 wt, ⌬VP1, or D9A/D13A/E17A for 16 h and prepared endosomes using floatation centrifugation in a sucrose step gradient (3, 18, 33) . Endosomes were found enriched in fraction 6, as indicated by Western blot analysis of gradient fractions for the endosomal marker protein Rab5 (Fig. 6B and C) . The endosomal fraction (EF) is well separated from soluble cytoplasmic proteins (indicated by anti-IB immunostaining), as well as from nuclear components (indicated by anti-lamin B immunostaining), which do not float during centrifugation (Fig. 6B) . For monitoring endosomal escape of AAV2 wt and the respective capsid mutants, the content of the viral genomes within endosome fractions of infected cells was analyzed by qRT-PCR. Recovered viral genomes were related to the size of the respective endosome fraction, which was characterized by Rab5 immunoblotting (Fig.  6C) and subsequently quantified by measuring the intensity of the bands (done with ImageJ). Figure 6D shows the relative amounts of viral genomes (percentage of viral genomes used for infection, "input") per endosome fraction. Analysis reveals that only low amounts of AAV2 wt remain in endosomes at 16 h postinfection (2.32%). In contrast, ⌬VP1 was recovered to a large extent from endosomes (69.37%), whereas only small amounts of mutant D9A/D13A/E17A could be found in the respective endosome fraction (11.37%). This observation indicates that the extranuclear localization of ⌬VP1 most likely results from a block in endosome escape, probably due to its complete lack of PLA 2 activity. However, capsid mutant D9A/ D13A/E17A is to a great extent able to escape from endosomes. Thus, the PDZ-binding motif mutant seems to be unable to penetrate the nuclear envelope.
DISCUSSION
As intracellular trafficking, capsid processing, and nuclear uptake limit AAV's transduction efficiency, an increasing number of studies have been dedicated to elucidate virus-cell interactions involved in these postentry steps (13, 15, 21, 25, 29, 42, 44, 50, 60, 63, 64) . A hallmark of AAV postentry processing is the exposure of the VP1/2 N termini on AAV capsids during a productive infec- tion (50) . Thus far, two sequence motifs located on the VP1/2 N termini have been shown to influence the AAV2 infection process. Three basic regions play a role in AAV2 infectivity; BR3 has been suggested to be required for nuclear import and intranuclear localization of capsids (19, 29) . Furthermore, the PLA 2 catalytic domain is required for AAV2 infectivity, by enabling endosomal escape of virions (16, 17, 51) . In this report, we describe additional protein sequence motifs located on the N terminus of capsid protein VP1, which inhibit AAV2 infection at some postentry stage, when mutated. However, the tight and overlapping arrangement of the sequence motifs makes the mapping of their distinctive function difficult.
Except for the three PDZ-binding motifs, the protein sequence motifs analyzed in the present study are overlapping with the PLA 2 domain and negatively influence its catalytic activity (Fig. 4) . In order to clarify whether the observed infection deficiency of the respective capsid mutants is functionally linked to the lack of PLA 2 activity, we investigated a single step of the infection process, which presumably does not require PLA 2 activity, namely, intracellular trafficking. By analyzing this step, we could show that an SH2-binding motif acts independently of the PLA 2 activity on intracellular routing of AAV2. Deletion of the entire VP1 N terminus, as well as a point mutation of this sequence motif, showed not only a requirement of the VP1 N terminus in total but also a requirement of this specific sequence for this step of infection. Concomitantly, we found that perinuclear accumulation is not dependent on PLA 2 activity, as the PLA 2 -defective mutant H75A/ D76N was able to accumulate at the nucleus in a wt-like fashion. It was not possible to assign a PLA 2 -independent activity to the other infection-deficient VP1 N-terminal AAV2 capsid mutants because they showed a similar phenotype as H75A/D76N in the assays used here.
Perinuclear accumulation is a typical feature of parvovirus infection (11, 45) . During their passage through endosomal compartments and consequent perinuclear accumulation, the VP1/2 N termini of AAV2 become exposed, thereby presenting their PLA 2 domain, along with all other N-terminal sequence motifs at the capsid surface. Among the VP1/2 N-terminal mutants analyzed in the present study, two clearly distinctive phenotypes could be observed; whereas AAV2 wt and the PLA 2 -defective H75A/D76N mutant accumulated closely around the nucleus in a typical pattern, the VP1 deletion mutant ⌬VP1 and the 79 YXXQ mutant Y79A/Q82A were predominantly found scattered throughout the cytoplasm with only few virus particles accumulating at the nuclear rim. From this we can conclude that the SH2-binding motif, 79 YXXQ ( 79 YDRQ), influences the intracellular trafficking pattern of AAV2 and is thus possibly involved in directional intracellular virus transport, leading to perinuclear accumulation of AAV2. Since the Y79A/Q82A mutant is able to externalize its VP1 N terminus after limited heat treatment and during infection (Fig. 3) , we can exclude the possibility that the observed diffuse distribution pattern of mutant viruses is caused by a defect in VP1 N terminus externalization.
The 79 YXXQ motif of AAV2 is a tyrosine-based SH2-binding motif. SH2-binding motifs are recognized by Src homology 2 (SH2) domains, which are widespread protein-protein interaction modules that bind to specific SH2-binding motifs containing a phosphorylated tyrosine residue. A great number of tyrosine-based signaling proteins, including kinases, phosphatases, and adapter proteins, can be assembled into multiprotein signaling complexes via interactions between their SH2 domains and phosphotyrosines (48) . However, SH2-binding occurs in the cytoplasm, and thus exposed VP1 N termini need to access the cytoplasm in order to be able to interact with SH2 domains of cellular proteins. Since the Y79A/Q82A mutant lacks PLA 2 activity but influences at the same time routing of virus-loaded endosomal vesicles, the catalytic action of the PLA 2 domain cannot be responsible for penetration of the VP1 N termini through the endosomal membrane. Based on a structural modeling approach, the first 185 aa of the VP1 N terminus were predicted to be exposed through channels at the 5-fold axis of symmetry (34) . Since a sequence length of 18 to 20 aa is sufficient to span a phospholipid bilayer, it is conceivable that the VP1 N terminus may be threaded through the endosomal membrane to get access to cytoplasmic interaction partners. Which factors, other than the PLA 2 , could possibly generate access to the cytoplasm is still unknown.
After perinuclear accumulation, AAV2 particles are imported into the nucleus most probably as fully assembled capsids (5, 30, 47, 50, 60) . However, the mechanism of nuclear entry is currently not known. Grieger et al. (19) suggested that BR3 acts as a NLS and mediates nuclear import of AAV2 through the NPC. On the other hand, two studies argue in favor of a NPC-independent nuclear import mechanism (23, 60) . Hansen et al. (23) observed uptake of AAV particles into purified nuclei, which could not be inhibited by either WGA or anti-p62 Ab, both of which are known to block NPC-mediated nuclear import. Moreover, Xiao et al. (60) observed nuclear accumulation of AAV genomes after treatment with thapsigargin, an inhibitor of the endoplasmic reticulum/nuclear envelope-associated calcium pump that is known to block NPC-dependent nuclear import when cells are maintained in calcium free medium. For defining the sequences influencing virus nuclear entry, we sought to investigate the effect of three VP1 N terminus-located consecutive PDZ-binding motifs on AAV2 nuclear import. Infection of cells with ⌬VP1 or the PDZ-binding motif mutant showed that a lack of or mutation of the VP1 N terminus prevents nuclear uptake of AAV2 (Fig. 6A) . Although the lack of the entire VP1 N terminus hinders nuclear uptake indirectly by impairing endosomal escape, PDZ-binding motifs do not influence egress from endosomes ( Fig. 6D ) and may directly be involved in nuclear uptake of AAV2 capsids.
PDZ-binding motifs are recognized in a sequence-specific manner by PDZ domains (also called Discs-large homologous regions [DHR] or GLGF repeats), which are conserved protein modules of 80 to 100 aa, mediating protein-protein interactions and thus the formation of large protein interaction complexes mainly involved in signaling pathways (43) . There are a number of studies providing evidence for the existence of PDZ-binding motifs in viral proteins and their interaction with corresponding PDZ domain-containing proteins, for modulating cellular processes favoring viral propagation (reviewed in reference 28). We hypothesize that interactions between the virus capsid and components of the nuclear membrane may activate intranuclear factors, which in turn favor the permeabilization of the nuclear envelope, thereby permitting cytoplasmic-nuclear exchange and possibly virus entry. This speculation is supported by the findings of Cohen et al. (7) (8) (9) , who could demonstrate that the autonomous parvovirus MVM is able to induce the formation of electron microscopy-visible holes within the nuclear envelope of Xenopus oocytes nuclei. This was observed after microinjection of the virus but also after the infection of intact mouse fibroblasts (7, 8) . These authors suggest a caspase-dependent mechanism that is independent of the catalytic activity of the VP1 N terminus-encoded PLA 2 domain. We therefore suggest that those three PDZ-binding motifs, which are located at the tip of the VP1 N terminus, might function as a sort of port key that allows AAV2 to enter the nucleus for uncoating and replication.
Improving the transduction efficiency and specificity of clinically relevant AAV-based gene therapy vectors, relies on detailed understanding of the gene transfer process. Our study provides new insights into molecular events of AAV2 intracellular transport and gene delivery into the nucleus. We identified several protein sequence motifs of the unique VP1 N terminus, which are essential for AAV2 infection. In particular, 79 YXXQ is involved in intracellular routing of virus particles and three PDZ-binding motifs play a role in virus nuclear uptake. This information has to be integrated into strategies to design capsid-modified AAV vectors with improved transduction profiles.
